Skip to search formSkip to main contentSkip to account menu

APC8015F

Known as: APC 8015F 
A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
Control-arm patients from three prostate cancer clinical trials of sipuleucel-T (an autologous APC–based therapy) received APC… 
2013
2013
Lower baseline PSA predicts greater benefit from sipuleucel-T.
Sipuleucel-T (Provenge, Dendreon) is an autologous cellular immunotherapy that is approved by the US Food and Drug Administration… 
2012
2012
Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-T in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC).
e15120 Background: Sipuleucel-T is an autologous cellular immunotherapy approved for asymptomatic or minimally symptomatic mCRPC… 
2011
2011
Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies.
4534 Background: Sipuleucel-T is an autologous cellular immunotherapy approved by the FDA for the treatment of asymptomatic or… 
2011
2011
2011 American Society of Clinical Oncology Annual Meeting
2011
2011
Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies.
139 Background: Sipuleucel-T is an autologous cellular immunotherapy approved for metastatic castrate resistant prostate cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)